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ABSTRACT
Background. Approximately 5–8% of melanoma patients
will develop in-transit metastases (IT-mets). Tumor
necrosis factor-a (TNF) and melphalan-based isolated limb
perfusion (TM-ILP) is an attractive treatment modality in
melanoma patients with multiple IT-mets. This study
reports on a 20 years experience and outlines the evolution
and major changes since the introduction of TNF in ILP.
Methods. A total of 167 TM-ILPs were performed in 148
patients, between 1991 and 2009. TM-ILPs were per-
formed at high doses of TNF (3–4 mg) from 1991 to 2004
(n = 99) and at low doses of TNF (1–2 mg) from 2004 to
2009 (n = 68) under mild hyperthermic conditions (38C–
39.5C.). Melphalan doses were unchanged at 10–13 mg/l
(leg and arm, respectively). Characteristics for the 167
ILPs were: 81 stage IIIB, 65 stage IIIC, and 21 stage IV
disease.
Results. The overall response rate was 89% (n = 148).
(Complete response [CR] = 61%; partial response
[PR] = 28%). CR rates correlated with stage (P = .001)
and with high-dose vs. low-dose TNF (70% vs. 49%;
P\.006). High-dose TNF prolonged local control (med-
ian 16 months vs. 11 months; P = .076). Survival was not
inﬂuenced by TNF dose. CR after ILP and number of
lesions also correlated with local progression-free interval.
Overall survival did correlate with stage of disease
(P\.001), size of the lesions (P = .001), and a CR
(P\.001).
Conclusions. This 2-decade single-center experience
demonstrates that TM-ILP is a safe and effective treatment
modality for melanoma patients with multiple IT-mets.
Higher dose of TNF was associated with signiﬁcantly
higher CR rates and prolonged local control without an
effect on overall survival.
Malignant melanoma incidence is rising rapidly. In 2008
there were approximately 62,000 new cases of primary
melanoma in the United States, of which approximately
50% were extremity melanoma.
1 In 5–8% of cases, mela-
noma patients will develop in-transit metastasis (IT-mets).
As regional recurrence often precedes systemic disease,
amputative surgery is in general no longer practiced,
although old series of radical surgery have demonstrated
that some patients with IT-mets conﬁned to the limb can be
cured.
2,3 Simple surgical resection may sufﬁce for inci-
dental and low numbers of IT-mets, but in cases of rapid
recurrences and multiple IT-mets, isolated limb perfusion
(ILP) provides an attractive treatment option that can
improve local control markedly and thereby quality of life.
ILP, developed by Creech et al., achieves a 20-fold
higher concentration of chemotherapeutic drugs when
compared with systemic therapy.
4,5 Melphalan-based ILP
(M-ILP) has been the standard treatment and has been
reported to achieve overall complete response (CR) rates in
the range of about 50%.
6 In general large IT-mets showed a
poor response and inhomogeneous uptake comparable with
locally advanced soft tissue sarcomas (STS). The intro-
duction of tumor necrosis factor-a (TNF) changed this
situation dramatically. Large tumors now reacted very well
to ILP.
7 This led to a successful multicenter trial in Europe
and the approval of TNF-based ILP (TM-ILP) for irre-
sectable extremity soft tissue sarcomas (STS).
8 Similar
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ILP for melanoma patients.
9 Preclinical and clinical studies
suggested that a reduction of the dose of TNF to 1 mg for
the arm and 2 mg for the leg might be as effective as the
higher doses.
10–13 Therefore, we changed TNF doses from
4 to 2 mg for ILP of the leg and from 3 to 1 mg for an ILP
of the arm starting in 2004. This study reports on our
20-year experience, analyzes the determinants of response
and toxicity in patients with multiple melanoma IT-mets of
the limb, and outlines the evolution and major changes
since the introduction of TNF in ILP.
PATIENTS AND METHODS
Patients
Between 1991 and 2009, 173 ILPs were performed in
patients with extensive melanoma IT-mets in the limb. For
5 patients clinical data were insufﬁcient because they came
from abroad and did not have adequate follow-up in our
center. One patient died 4 days after ILP without any
leakage of TNF as a result of a myocardial infarction
(mortality: 0.6%). There were 13 patients who underwent
ILP twice because of recurrence. Also, 3 patients under-
went 3 perfusions. As a result 167 ILPs in 148 patients
were included for analysis (Fig. 1).
As a result of publications in literature indicating that in
sarcoma patients a lower dose of TNF might be as effective
as a high dose, we lowered the dose of TNF in 2004 in our
center from 3–4 mg to 2 mg for a lower limb perfusion and
from 3 to 1 mg for an upper limb perfusion.
11,14 High-dose
TNF perfusions between 1991 and 2004 (n = 99) and low-
dose TNF perfusions between 2004 and 2009 (n = 68) were
compared. All demographic data, disease presentation, and
ILP characteristics were retrieved from a prospectively
maintained database.
Treatment
The technique of ILP with TNF and melphalan has been
described previously.
15,16 Brieﬂy, the procedure is per-
formed with patients under general anesthesia. After
heparinization, a targeted blood circuit is isolated by
clamping and cannulation of the major artery and vein and
connected to an oxygenated extracorporeal circuit. A
tourniquet compresses collateral vessels and prevents
leakage. Using a precordial scintillation probe to detect
technetium-labeled albumen, leakage is monitored for the
length of the procedure. The standard dose of TNF in the
1st decade was 3 mg for the arm and 4 mg for the leg.
Currently, a dose of 1 mg in the arm or 2 mg in the leg of
recombinant TNF-a (Boehringer Ingelheim GmbH, Ingel-
heim/Rhein, Germany) is injected as a bolus once the
temperature of the limb reached 38C. Subsequently,
13 mg/l (arm) or 10 mg/l (leg) melphalan (L-PAM,
Alkeran, Burroughs Wellcome Ltd., London, UK) was
administered 30 min after the limb temperature reached
38–39.5C. The doses of melphalan were not changed
during the last 2 decades and have been standardized for
more than 40 years. After 90 min of perfusion, the limb is
washed out with 1 l (arm) to 4 l (iliac perfusion) of
physiological saline solution and 6% dextran (Macrodex
Pharmacia, Uppsala, Sweden).
Response and Toxicity
Clinical response was obtained 2–4 weeks and 8 weeks
after ILP. Afterwards, follow-up was 3 monthly in the ﬁrst
2 years after ILP and at longer intervals thereafter.
Response rates were deﬁned according to WHO criteria.
17
Toxicity after ILP was classiﬁed following Wieberdink
et al.
18
Statistical Evaluation
Overall survival (OS) and time to local or systemic
progression (TLP/TSP) were deﬁned as time between ILP
and death, local progression, or systemic progression,
respectively. The end of follow-up was deﬁned as the last
visit to the outpatient clinic. On January 1, 2011 the
community death register was consulted to determine OS.
Estimates were drawn using the Kaplan-Meier method.
19
Prognostic value of baseline factor as used in previous
literature was evaluated for 3 endpoints (TLP/TSP/OS)
using Cox regression and was expressed in hazard
ratios.
16,20–28 Prognostic value of the same factors for CR
was determined using logistic regression and analogously
167
inclusions
5
LTFU
1
POD
3
primaries
173
IT-Mets
321
sarcomas
176
melanomas
536
TM-ILPs
38
miscellaneous
FIG. 1 Inclusion ﬂow chart. TM-ILP TNF-based ILP, IT-Mets in-
transit metastasis, LTFU lost through follow-up, POD perioperative
death
628 J. P. Deroose et al.expressed in odds ratio. Multivariate analysis was per-
formed with all factors that reached 10% signiﬁcance in
univariate analysis. A stepwise backward algorithm was
used to exclude factors without signiﬁcant prognostic
value. To compare baseline factors within the 2 groups a
t test was used. All tests were done at a signiﬁcance level of
5%.
RESULTS
Patients
In total, 167 TM-ILP were analyzed in 148 subsequent
patients. Median age of patients was 65 years (range,
25–93); 103 patients (70%) were female. Median follow-up
was 20 months (range, 1–130). Disease staging was
according to the AJCC staging system, which resulted in 81
cases (48%) with stage IIIB, 65 cases (39%) with stage IIIC,
and stage IV in 21 cases (13%).
29 All demographic, disease
presentation, and ILP characteristics are summarized in
Table 1.Most remarkable evolutions on characteristics over
time were a shift toward older patients (P = .030), shorter
period between diagnosis and TM-ILP (P = .001), and
smaller lesions (P = .016).
Treatment
Patients underwent ILP via the axillary (n = 7, 4%),
iliac (n = 85, 51%), and femoral (n = 75, 45%) approach.
A signiﬁcant shift from an iliacal approach to a femoral
approach was observed in the later years, (P = .003,
Table 2). Hospital length of stay decreased for every per-
fusion type (Table 2).
Response Rate and Limb Function
An overall response rate of 89% (n = 148) was
observed. In 102 cases (61%) a CR was recorded, 46
patients (28%) had a partial response (PR), and 19 (11%)
had no change (NC). Patients treated with a high-dose TM-
ILP had a CR rate of 70% compared with a CR rate of 49%
for those treated with a low-dose TM-ILP (P = .006).
A CR was signiﬁcantly more often observed in patients
with stage IIIB disease (77%) compared with patients with
stage IIIC or IV disease, 49% vs. 38%, respectively (IIIB
vs. IIIC, P = .002; IIIB vs. IV, P = .003; IIIC vs. IV,
P 0.45). In multivariate analysis TNF dose, stage of dis-
ease, and age remained signiﬁcant prognostic factors for
CR (Table 3).
Limb function was assessed in all 148 patients, which
resulted in perfect function in 118 cases (80%), loss of
function without the necessity of using crutches in 15 cases
(10%), and 4 cases (3%) of severe limb function loss
necessitating crutches. In 2 patients (1.5%) an amputation
was necessary because of post-ILP locoregional toxicity
(Wieberdink grade V). In 8 patients (6%) an amputation
was necessary because of uncontrollable ulcerating loco-
regional tumor recurrences (n = 8), In 1 patient an
TABLE 1 Patient and tumor characteristics
High-dose
(1991–2004)
Low-dose
(2004–2009)
Total
(1991–2009)
P
value
Sex
Female 62 (71%) 41 (67%) 103 (70%) .598
Male 25 (29%) 20 (33%) 45 (30%)
Age
\65 years 55 (56%) 26 (37%) 81 (49%) .030
C65 years 44 (44%) 42 (63%) 86 (51%)
Location primary
Arm 3 (3%) 2 (3%) 5 (3%) .737
Leg 47 (54%) 40 (67%) 87 (59%)
Foot 29 (34 %) 16 (26%) 45 (31%)
Back 4 (5%) 2 (3%) 6 (4%)
Unknown primary 3 (3%) 1 (1%) 4 (3%)
Missing 1 – 1
Breslow
Median in mm (range) 2.89 (0.6–15.0) 3.00 (0.7–11.0) 2.97 (0.6–15.0) .579
Missing 25 (29%) 12 (20%) 37 (25%)
Primary to IT-mets
B1 year 30 (36%) 31 (52%) 61 (43%) .052
[1 year 53 (64%) 28 (48%) 81 (57%)
Missing 4 2 6
Time between IT-mets and ILP
B6 months 41 (42%) 46 (69%) 87 (53%) .001
[6 months 57 (58%) 21 (31%) 78 (47%)
Missing 1 1 2
Location
Arm 4 (4%) 3 (4%) 7 (4%) .906
Leg 95 (96%) 65 (96%) 160 (96%)
Number of lesions
\10 41 (41%) 37 (54%) 78 (47%) .098
C10 58 (59%) 31 (46%) 89 (53%)
Size largest
\40 mm 53 (53%) 49 (72%) 102 (61%) .016
C40 mm 46 (47%) 19 (28%) 65 (39%)
AJCC stage
IIIB 46 (47%) 35 (52%) 81 (48%) .706
IIIC 39 (39%) 26 (38%) 65 (39%)
IV 14 (14%) 7 (10%) 21 (13%)
Prior treatment
None 59 (60%) 56 (82%) 115 (69%) .019
ILP 17 (17%) 8 (12%) 25 (15%)
RTx 3 (3%) 2 (3%) 5 (3%)
CTx 9 (9%) – 9 (5%)
Immuno 4 (4% 1 (2%) 5 (3%)
Combination 7 (7%) 1 (2%) 8 (5%)
ILP isolated limb perfusion, RTx radiotherapy, Ctx chemotherapy, Immuno
immunotherapy
TNF Dose Matters in ILP for Melanoma 629amputation was necessary for arthrosclerosis despite a CR.
In case of amputation, median time span between ﬁrst ILP
and amputation was 17 months (mean 19, range 2–32).
Local Progression
Local progression after ILP occurred in 56% of cases
(n = 93) after a median time of 13 months. Although not
signiﬁcant, a trend towards better local control could be
observed in the high dose TM-ILP group. Median time to
local progression (TLP) was 16 months after high dosed
TM-ILPs while those treated after TNF dose reduction
showed a median TLP of 11 months (P = .076, Fig. 2c).
Patients with a CR after ILP had a signiﬁcantly longer
median TLP of 19 months, whereas a PR or NC resulted in
a median TLP of 6 months (P\.001). Patients treated for
C10 lesions had a shorter TLP compared with those with
\10 lesions. (9 vs. 24 months, respectively, P = .002). CR
after ILP and number of lesions remained signiﬁcant
prognostic factor for local progression in multivariate
analysis (Table 3).
Systemic Disease
Patients treated with curative intent (stage IIIB and IIIC,
n = 146) developed systemic disease (stage IV) in 79 cases
(54%) with a median time to systemic progression (TSP) of
26 months. Patients with a CR had a median TSP of
39 months, whereas patients with PR or NC showed a
median TSP of 11 months (P\.001). Female sex
(P\.001), the size of the largest lesion (P = .002), and
stage of disease (P\.001) were baseline factors reaching
signiﬁcance in univariate Cox regression analysis. Sex,
size, stage of disease, and response to ILP remained sig-
niﬁcant prognostic factors for TSP in multivariate analysis.
The dosage of TNF was not of inﬂuence on TSP
(P = .236). Once patients developed systemic disease,
median survival time was 7 months.
Survival
The overall actuarial 3-year, 5-year, and 10-year survival
rates after ILP were 40% (±4%), 26% (±4%), and 13%
(±3%), respectively; median OS was 24 months. CR after
perfusion resulted in a prolonged median OS of 44 months,
while patients with PR or NC had a median survival of
11 months (Fig. 2a, P\.001). When data were stratiﬁed
for stage of disease, 5-year survival was 42% for stage IIIB
disease, 15% for stage IIIC disease, and 0% for stage IV
disease (Fig. 2b, P = .001). In univariate regression anal-
ysis, female sex (P\.001), age (P = .004), a primary on
the limb (P = .009), Breslow thickness (P = .003), small
size of IT-mets (P\.001), and long interval between
diagnosis of IT-mets and perfusion (P = .003) appeared to
be other favorable prognostic factors correlated with pro-
longed survival. In multivariate analysis age, small size,
lower stage of disease, and complete response after ILP
remained signiﬁcant prognostic factors for prolonged sur-
vival. Analogously to time to systemic progression, dose of
TNF was not associated with OS (P = .272, Fig. 2d). All
hazard ratios are summarized in Table 3.
Body Mass Index
Patients with a body mass index (BMI)[30 had a CR
rate of 63% (n = 19), which is similar to the CR rate of
60% for those with a BMI of B30 (P = .78). Median TLP
was 13 months for patients with a BMI B 30, while
patients with a BMI[30 had a median TLP of 12 months
(P = .82). In univariate analysis, BMI as prognostic
baseline factor did not reach signiﬁcance for clinical out-
come, nor for TLP, TSP, or OS.
Leakage and Toxicity
Local toxicity was not observed (Wieberdink I) in 31
cases (18%), slight (Wieberdink II) in 93 cases (56%),
TABLE 2 Treatment characteristics
High dose (1991–2004) Low dose (2004–2009) Total (1991–2009) P value
Type of ILP
Axillary 4 (4%) 3 (4%) 7 (4%) .003
Iliacal 61 (62%) 24 (35%) 85 (51%)
Femoral 34 (34%) 41 (60%) 75 (45%)
Ax Il Fem Ax Il Fem Ax Il Fem
Dose (mg)
Median melphalan 46 110 60 40 98 60 42 110 60
Hospitalization
Median days 14 11 10 5 8 6 10 10 8
Ax axillar, il iliacal, fem femoral, ILP isolated limb perfusion, TNF tumor necrosis factor a
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TNF Dose Matters in ILP for Melanoma 631considerable (Wieberdink III) in 38 cases (23%), and
severe (Wieberdink IV) in 3 cases (2%). Amputation due to
perfusion reaction was necessitated for 2 patients (1%), one
after 2 months, the other after 6 months. The dose of TNF
could not be identiﬁed as signiﬁcant predictor for local
toxicity (P = .524).
There was no or minor leakage (B10%) in 160 ILPs
(96%), median leakage was 0% (mean, 1.34; range, 0–25).
Leakage was [10% in 7 patients of which 1 patient with
12% systemic leakage had a myocardial infarction 2 days
after ILP; after referral to a cardiac department this patient
was stabilized, had no further complications, and was
discharged from hospital after 8 days. There were 2 other
patients who experienced transient hypotension treated
with vasopressors. Also, 1 patient had a grade IV leuco-
penia that lasted for 1 day, which did not need any
intervention. There were 3 patients who did not experience
any inconvenience of the[10% systemic leakage.
DISCUSSION
With an overall response (OR) rate of 89% and a CR
rate of 61%, the present study demonstrates that TM-ILP is
a successful treatment modality in obtaining local control
of the limb in patients with melanoma in-transit metastases.
Local and systemic toxicity is limited, which emphasizes
the safety of this procedure. The reduction of the dose of
TNF was associated with a lower CR rate.
The introduction of TNF ushered in a new era for ILP in
Europe. The present study reported on the evolution
observed over the past 2 decades. The most remarkable
change was the dose reduction of TNF based on several
previous studies describing comparable response rates with
reduced local toxicity.
10,11,13,14 In the present series, a CR
was more often observed in the period of high dose TM-
ILPs. In multivariate analysis this difference remained
signiﬁcant.
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632 J. P. Deroose et al.The lowering of the dose of TNF not only led to inferior
clinical response, but to an inferior local control as well.
This was emphasized by the fact that there were no cases of
maintained local control after 3 years in the low-dose TNF
group (Fig. 2c). There was no signiﬁcant correlation
between the dose of TNF and systemic progression or OS.
These ﬁndings ﬁt in the concept of a locoregional treatment
having locoregional beneﬁt only. In our opinion, CR after
TM-ILP occurs in patients with the more favorable biol-
ogy, which allows a similar effect after low-dose
perfusions.
16 Patients with more unfavorable biology might
experience more often a CR and prolonged local control
after high-dose perfusion compared with low-dose perfu-
sion. However, systemic development and overall survival
are dictated by the biology of the tumor, which explains
that despite lower response rates and inferior local control
low-dose perfusions show similar TSP and OS. This is
illustrated in Fig. 2c and d.
The dose reduction of TNF in ILP for melanoma
patients was mainly based on data in sarcoma patients. Our
group published in 2005 a mixed series of sarcoma and
melanoma patients with only 16 melanoma patients who
received low-dose TNF.
14 Rossi et al. described a series of
20 low-dose perfusions in melanoma patients.
13 The low
numbers of patients might explain why these studies did
not ﬁnd the correlation between dose of TNF and CR rate
and local control. Our series is one of the largest in the
world with a mature follow-up, and therefore the outcome
might be different compared with our previous, smaller
series.
There is no consensus in the literature about the beneﬁt
of using TNF in ILP for IT-mets in melanoma patients.
Cornett et al. performed the only randomized controlled
trial so far in which they report an increased local and
systemic toxicity without any beneﬁcial effect in clinical
response (CR rate 26% for TM-ILP vs. CR rate 25% for
M-ILP).
30 This study was subject of several criticisms, so
their conclusions should be read with caution.
31 First of all,
they reported complete response rate after 3 months, which
is an uncommon endpoint since a substantial proportion of
patients reach CR between 3 and 6 months. Secondly, there
was very little data provided concerning differences
between patients and tumor characteristics between both
arms. Thirdly, the true indication for TNF-based ILP, bulky
disease was not analyzed.
Alexander et al. reported recently the long-term fol-
low-up results of a mixed TM-ILP and M-ILP series.
20
They did not identify a signiﬁcant correlation between
the addition of TNF to M-ILP and inﬁeld progression,
which might be explained by the lower number of
patients included in this study. The reported CR rate of
69% is slightly higher compared with ours in a more
favorable patient population (68% stage IIIA disease in
their group vs. 48% in the present study). Rossi et al.
reported a CR rate of 60% for TM-ILP and 42% for
M-ILP, which was a signiﬁcant difference (P = .05).
32
With the correlation between CR rate and local control
on one hand and the dose of TNF on the other, the
present study emphasizes the important role of TNF in
ILP for melanoma patients.
Certainly in bulky disease TNF is of additional value.
Melphalan uptake is very low in large tumors, which can
be improved by a 3- to 6-fold with the use of TNF.
33
Consequently, we consider TM-ILP indicated for patients
with bulky disease and those resistant for M-ILP. When
disease load is limited, melphalan-only based ILP might be
effective in achieving local control.
34,35 In cases of small
lesions restricted to the distal parts of the limb, isolated
limb infusion with melphalan can be of value.
36 Literature
suggests that reduction of duration of TM-ILP has no
inﬂuence on either clinical response or local control.
37
However, these results are achieved in soft tissue sarcoma
patients and should be investigated in an IT-mets mela-
noma study population.
A variety of treatment modalities for IT-mets have been
used with various successes. If lesions are limited in
number and size, simple surgical excision is the preferred
treatment modality. Smaller lesions too numerous for
excision were treated with carbon dioxide laser therapy,
intralesional injections, and electrochemotherapy, but all
with poor clinical response rates.
38–44 After decades of
failing to identify effective systemic therapy, there are
promising results achieved with PLX4032 and ipilimumab
in patients with stage III and IV disease. PLX4032
(vemurafenib) provides a rather limited PFS of only
5.5 months in irresectable stage III–IV disease and ipi-
limumab a response rate of only about 10%, so the role of
ILP remains established while that of these new drugs in
the treatment for IT-mets is still unclear.
45–47
TNF increases the efﬁcacy of ILP. We demonstrated
that high doses of TNF are correlated with higher CR rates
and superior local control in patients with high tumor
burden and those having failed previous therapy. Since the
main objective of TM-ILP in melanoma patients is
obtaining local control, rather than improving survival,
high-dose TNF perfusions seem preferable to low-dose
TNF perfusions.
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